Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by mercedesmanon Jul 26, 2021 12:03pm
123 Views
Post# 33604532

Prospectus Supplement

Prospectus SupplementTO A SHORT FORM BASE SHELF PROSPECTUS DATED JULY 3, 2020

S-12 and S-13


...The Company has granted to the Underwriters an Over-Allotment Option, exercisable, in whole or in part, at the sole discretion of the Underwriters, at any time, and from time to time, for a period of 30 days from and including the Closing Date, to purchase: (i) up to an aggregate of 3,529,500 Over-Allotment Units at the Offering Price; (ii) up to an aggregate of 3,529,500 Over-Allotment Shares at a price of $0.397 per Over-Allotment Share; (iii) up to an aggregate of 1,764,750 Over-Allotment Warrants at a price of $0.055 per Over-Allotment Warrant; or (iv) any combination of (i), (ii) and (iii) provided that, in each case, the aggregate number of Over-Allotment Shares and the

aggregate number of Over-Allotment Warrants that may be issued under the Over-Allotment Option (in each case either as underlying components of the Over-Allotment Units or otherwise) does not exceed 3,529,500 Over-Allotment Shares and 1,764,750 Over-Allotment Warrants, to cover over-allocations, if any, and for market stabilization purposes. The Over-Allotment Units and Over-Allotment Warrants have the same terms as the Units and the Warrants. This Prospectus also qualifies the grant of the Over-Allotment Option and the distribution of the securities to be issued upon exercise of the Over-Allotment Option. A person who acquires securities forming part of the Underwriters’ over-allocation position acquires those securities under this Prospectus regardless of whether the Underwriters’ over-allocation position is ultimately filled through the exercise of the Over-Allotment Option or secondary market purchases.
In consideration for the services provided by the Underwriters in connection with the Offering, and pursuant to the terms of the Underwriting Agreement, the Company has agreed to pay the Underwriters the Underwriters’ Fee equal to 6.5% of the gross proceeds from the Offering (including any gross proceeds raised on exercise of the Over-Allotment Option). The Underwriters will also receive Broker Warrants to purchase that number of Broker Shares that is equal to 6.5% of the Units sold pursuant to the Offering (including any exercise of the Over- Allotment Option). Each Broker Warrant is exercisable to purchase one Broker Share at a price of $0.486 for a period of 24 months from the Closing Date. This Prospectus also qualifies the distribution of the Broker Warrants....
<< Previous
Bullboard Posts
Next >>